RT is a next-generation triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, making it one of the most exciting compounds in metabolic research.
Researchers study Retatrutide for:
- Body weight regulation
- Appetite and satiety signaling
- Energy expenditure research
- Glucose metabolism
- Cardiometabolic health
- Obesity and metabolic science
Its triple-action mechanism differentiates RT from traditional metabolic peptides and positions it at the forefront of next-generation research.
For laboratory research purposes only. Not approved for human use.
Reviews
There are no reviews yet.